Plain-English translation of NCT07096908 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing , a medication that works by mimicking natural gut hormones to help with weight loss. The medication has shown strong results in people without diabetes, but doctors don't yet know how well or safely it works specifically for people who have both type 1 diabetes and obesity. This study will compare the medication to a placebo (inactive injection) over 76 weeks to find out.
While this medication is already approved and used for obesity treatment in Europe and the Gulf region, its safety and effectiveness in people with type 1 diabetes has never been studied — even though more than a quarter of people with type 1 diabetes in Kuwait also struggle with obesity. Understanding how this treatment works in this specific group could change how doctors help these patients in the future.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive either the medication or a placebo as a weekly injection under your skin for 76 weeks (about 18 months). The dose starts low and gradually increases over the first 6 months to help your body adjust. You'll visit the study center regularly so doctors can monitor your weight, blood sugar, and how you're tolerating the medication, and you'll continue wearing your glucose monitor throughout the entire study.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Kuwait